Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L12 pseudogene 11 (RPL12P11, also known as dJ661I20.1) is a human processed pseudogene related to the ribosomal protein L12 gene. Processed pseudogenes are non-functional sequences derived from functional genes, typically by reverse transcription of mRNA and subsequent genomic integration. RPL12P11 does not encode a functional protein and is not transcribed into functional RNA with biological activity. Unlike true ribosomal proteins, which are essential for protein synthesis, pseudogenes like RPL12P11 do not participate in ribosomal assembly, translational regulation, or cellular processes. They are accordingly absent from lists of drug targets and do not play a recognized role in human disease or therapy[4][8].\n\nIf you require details for the canonical functional form (RPL12, ribosomal protein L12), please clarify; RPL12 itself is a component of the large ribosomal subunit but even RPL12 is generally not considered a conventional drug target, except potentially in specialized research regarding ribosome-targeting agents[5][6].
None; no drugs target RPL12P11[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L12 pseudogene 11 (RPL12P11).